Cyclopentenyl cytosine inhibits cytidine triphosphate synthetase in paediatric acute non-lymphocytic leukaemiaa promising target for chemotherapy

European Journal of Cancer

Volumn 36, Issue 5, 2000, Pages 627-635

  Verschuur, A C ^a   Van Gennip, A H ^a   Leen, R ^a   Muller, E J ^a   Elzinga, L ^a   Voute P A ^a   Van Kuilenburg, A B P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Acute non lymphocytic leukaemia; CTP; Cyclopentenyl cytosine; Cytidine triphosphate synthetase; Ribonucleotides; UTP

Indexed keywords

1 (4,5 DIHYDROXY 3 HYDROXYMETHYL 2 CYCLOPENTEN 1 YL)CYTOSINE; CD34 ANTIGEN; CYTIDINE TRIPHOSPHATE; CYTIDINE TRIPHOSPHATE SYNTHASE; RIBONUCLEOTIDE; SYNTHETASE; UNCLASSIFIED DRUG;

ACUTE NONLYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW CELL; CELL SPECIFICITY; CELL TYPE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GRANULOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CARBON-NITROGEN LIGASES; CHILD; CHILD, PRESCHOOL; CYTIDINE; FEMALE; HUMANS; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; MALE; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED;

EID: 0034093433     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(00)00021-6     Document Type: Article

References (35)

1. Williams J.C., Kizaki H., Weber G. Increased CTP synthetase activity in cancer cells. Nature. 271:1978;71-72.
2. Weber G. Biochemical strategy of cancer cells and the design of chemotherapy. G.H.A. Clowes Memorial Lecture Cancer Res. 43:1983;3466-3492.
3. Kizaki H., Williams J.C., Morris H.P., Weber G. Increased cytidine 5′-triphosphate synthetase activity in rat and human tumors. Cancer Res. 40:1980;3921-3927.
4. Ellims P.H., Gan T.E., Medley G. Cytidine triphosphate synthetase activity in lymphoproliferative disorders. Cancer Res. 43:1983;1432-1435.
5. Van den Berg A.A., Van Lenthe H., Busch S., Van Kuilenburg A.B.P., Van Gennip A.H. The roles of uridine-cytidine kinase and CTP synthetase in the synthesis of CTP in malignant human T-lymphocytic cells. Leukemia. 8:1994;1375-1378.
6. Verschuur A.C., Van Gennip A.H., Muller E.J., Voûte P.A., Van Kuilenburg A.B.P. Increased activity of cytidine triphosphate synthetase in pediatric acute lymphoblastic leukemia. Adv. Exp. Med. Biol. 431:1998;667-671.
7. De Korte D., Haverkort W.A., De Boer M., Van Gennip A.H., Roos D. Imbalance in the nucleotide pools of myeloid leukemia cells and HL-60. correlation with cell-cycle phase, proliferation, differentiation and transformation Cancer Res. 47:1987;1841-1847.
8. Ravindranath Y., Andrew B.S., Yeager A.M.et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N. Engl. J. Med. 334:1996;1428-1434.
9. Politi P.M., Xie F., Dahut W.et al. Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemother. Pharmacol. 36:1995;513-523.
10. Glazer R.I., Cohen M.B., Hartman K.D., Knode M.C., Lim M.I., Marquez V.E. Induction of differentiation in the human promyelocytic leukemia cell-line HL-60 by the cyclopentenyl analogue of cytidine. Biochem. Pharmacol. 35:1986;1841-1848.
11. Moyer J.D., Malinowski N.M., Treanor S.P., Marquez V.E. Antitumor activity and biochemical effects of cyclopentenylcytosine in mice. Cancer Res. 46:1986;3325-3329.
12. Ford H., Cooney D.A., Ahluwalia G.S.et al. Cellular pharmacology of cyclopentenyl cytosine in Molt-4 lymphoblasts. Cancer Res. 51:1991;3733-3740.
13. Grem J.L., Allegra C.J. Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-β-D arabinofuranosylcytosine by cyclopentenyl cytosine. Cancer Res. 50:1990;7279-7284.
14. Campbell J., Rustum Y. Synergistic interaction between 3-deazauridine and arabinosylcytosine in mice bearing L1210 leukemia. Proc Am Assoc Cancer Res. 21:1980;277-281.
15. Grem J.L., Plowman J., Rubinstein L., Hawkins M.J., Harrison S.D. Modulation of cytosine arabinoside toxicity by 3-deazauridine in a murine leukemia model. Leukemia Res. 15:1991;229-236.
16. Weber G., Burt M.E., Jackson R.C., Prajda N., Lui M.S., Takeda E. Purine and pyrimidine enzymic programs and nucleotide pattern in sarcoma. Cancer Res. 43:1983;1019-1023.
17. Slingerland R.J., Bodlaender J.M., Van Lenthe H., Van Kuilenburg A.B.P., Van Gennip A.H. Imbalance between the pyrimidine ribonucleotide pools of rat pheochromocytoma PC-12 cells. Clin. Chem. Enzym. Comms. 5:1993;315-319.
18. Jackson R.C., Lui M.S., Boritzki T.J., Morris H.P., Weber G. Purine and pyrimidine nucleotide patterns of normal, differentiating and regenerating liver and of hepatomas in rats. Cancer Res. 40:1980;1286-1291.
19. De Korte D., Haverkort W.A., Roos D., Behrendt H., Van Gennip A.H. Imbalance in the ribonucleotide pools of lymphoid cells from acute lymphoblastic leukemia patients. Leukemia Res. 10:1986;389-396.
20. Verschuur A.C., Van Gennip A.H., Muller E.J., Voûte P.A., Vreken P., Van Kuilenburg A.B.P. Cytidine triphosphate synthase activity and mRNA expresssion in normal human blood cells. Biol. Chem. 380:1999;41-46.
21. Miltenyi S., Muller W., Weichel W., Radbruch A. High gradient magnetic cell separation with MACS. Cytometry. 11:1990;231-238.
22. Schmitz B., Radbruch A., Kummel T.et al. Magnetic activated cell sorting (MACS) - a new immunomagnetic method for megakaryocytic cell isolation. Comparison of different techniques Eur. J. Haematol. 52:1994;267-275.
23. Vervoordeeldonk S.F., Merle P.A., Behrendt H.et al. PCR-positivity in harvested bone marrow predicts relapse after transplantation with autologous purged bone marrow in children in second remission of precursor B-cell acute leukaemia. Br. J. Haematol. 96:1997;395-402.
24. Ruiz ME. Tissue culture techniques. In Schrader WT, O'Malley BW, eds. Laboratory Methods Manual for Hormone Action and Molecules in Endocrinology, 12th edn. Houston, Houston Biological Association 1988, 14:3-14:38.
25. De Korte D., Haverkort W.A., Van Gennip A.H., Roos D. Nucleotide profiles of normal human blood cells determined by high-performance liquid chromatography. Anal. Biochem. 147:1985;197-209.
26. Smith P.K., Krohn R.I., Hermanson G.T.et al. Measurement of protein content using bicinchonic acid. Anal. Biochem. 150:1985;76-85.
27. Van Kuilenburg A.B.P., Elzinga L., Verschuur A.C., Van den Berg A.A., Slingerland R.J., Van Gennip A.H. Determination of CTP synthetase in a crude cell homogenate by a fast and sensitive non-radiochemical assay using anion-exchange high performance liquid chromatography. J. Chromatogr. 693:1997;287-295.
28. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal. Biochem. 83(2):1977;346-356.
29. Denton J.E., Lui M.S., Aoki T.et al. Enzymology of pyrimidine and carbohydrate metabolism in human colon carcinomas. Cancer Res. 42:1982;1176-1183.
30. Van Kuilenburg A.B.P., Van den Berg A.A., Meinsma J.R., Slingerland R.J., Van Gennip A.H. Inhibition of CTP synthetase induces differentiation of HL-60 and down-regulation of the c-myc oncogene. Adv. Exp. Med. Biol. 370:1995;761-764.
31. Gharehbaghi K., Zhen W., Fritzer-Szkeres M., Szekeres T., Jayaram H.N. Studies on the antitumor and biochemical actions of cyclopentenyl cytosine against human colon carcinoma HT-29 in vitro and in vivo. Life Sci. 64:1999;103-112.
32. Volpe D.A., Du D., Grieshaber C.K., Murphy M.J. In vitro characterization of the myelotoxicity of cyclopenetenyl cytosine. Cancer Chemother. Pharmacol. 34:1994;103-108.
33. Meuth M. The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells. Exp. Cell Res. 181:1989;305-316.
34. Lillemark J.O., Plunkett W. Regulation of 1-β-D arabinofuranosylcytosine 5-triphosphate accumulation in human leukemia cells by deoxycytidine 5-triphosphate. Cancer Res. 46:1986;1079-1083.
35. Hiddemann W., Schleyer E., Unterhalt M., Kern W., Buchner T. Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal blood cells. Ther. Drug Monit. 18:1996;341-349.